Fig. 8
From: Osteocytic vinculin controls bone mass by modulating Mef2c-driven sclerostin expression in mice
Working model. In osteocytes, vinculin normally binds to transcription factor Mef2c in the cytoplasm and thereby blocks the nuclear translocation of Mef2c and inhibits Sost gene expression, thus activating the Wnt/β-catenin pathway and promoting bone formation and bone mass. In the absence of vinculin, Mef2c is translocated into the nuclei in osteocytes where it activates Sost expression, thus inhibiting the Wnt/β-catenin pathway and reducing bone formation and bone mass
